drugset / Trial / NCT00001304

Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34

NCT00001304

RandomizedParallel-groupOpen-labelTreatment

Summary

This study has been important in establishing synthetic human parathyroid hormone 1-34 (PTH) as a beneficial treatment for hypoparathyroidism, superior to conventional therapy with calcium and calcitriol. Providing synthetic human parathyroid hormone 1-34 (PTH) to patients who are unresponsive to conventional therapy has enabled severe cases of hypoparathyroidism to be managed effectively with the investigational drug, PTH. The primary goals of this study are to (1) provide long-term PTH therapy to patients who do not respond to conventional therapy; (2) understand the long-term effect of therapeutic PTH replacement on kidney function and bone mineral density; (3) study and track linear growth and bone accrual in children with hypoparathyroidism. (4) determine if subjects reach a normal level of peak bone mass and if the timing of this is comparable to normal age-matched healthy controls.

Timeline

Start
1991-10
Primary completion
2014-03
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcitriol Small molecule Oral
Subject Teriparatide Protein / enzyme biologic Subcutaneous
Background Calcium carbonate Other / unclassified 1000 mg Oral

Indications